MRG003
Sponsors
Groupe Oncologie Radiotherapie Tete Cou, Shanghai Miracogen Inc., Groupe Oncologie Radiotherapie Tete et Cou, Jiyan Liu, Fujian Cancer Hospital
Conditions
Advanced Solid TumorsAdvanced or Metastatic Biliary Tract CancerAdvanced or Metastatic Gastric CancerAdvanced or Metastatic Gastroesophageal Junction CarcinomaCarcinoma, Non-Small-Cell LungLocal RecurrenceLocally Advanced Head and Neck Squamous Cell CarcinomaNasopharyngeal Carcinoma
Phase 1
A Study of MRG003 in Patients With Advanced Solid Tumors
CompletedNCT04868344
Start: 2018-05-09End: 2021-03-29Updated: 2021-04-30
MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma
Not yet recruitingNCT07054307
Start: 2025-07-30End: 2030-07-30Target: 10Updated: 2025-07-08
Phase 2
A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer
NCT04838964
Start: 2021-04-28End: 2024-11-30Target: 80Updated: 2021-12-29
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
NCT04838548
Start: 2020-09-04End: 2023-02-28Target: 90Updated: 2021-04-09
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
RecruitingNCT04868162
Start: 2021-04-23End: 2026-12-31Target: 116Updated: 2025-07-08
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
Active, not recruitingNCT05126719
Start: 2023-04-06End: 2026-12-30Target: 238Updated: 2026-02-06
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.
NCT05188209
Start: 2021-05-24End: 2023-08-01Target: 60Updated: 2022-01-12
Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck
Not yet recruitingNCT06959108
Start: 2025-10-31End: 2029-10-31Target: 106Updated: 2025-09-02
Randomized Phase 2 trial of induction treatment of anti-PD-1 pucotenlimab and EGFR-ADC MRG003 or EGFR-ADC alone followed by chemoradiotherapy in locally advanced head and neck squamous cell carcinoma (LA-SCCHN).
RecruitingCTIS2023-510558-18-00
Start: 2025-10-13Target: 106Updated: 2025-06-24
MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
Not yet recruitingNCT07331428
Start: 2026-01-01End: 2029-12-31Target: 25Updated: 2026-01-09